NanoViricides Financials

NNVC Stock  USD 1.13  0.01  0.88%   
Based on the key indicators related to NanoViricides' liquidity, profitability, solvency, and operating efficiency, NanoViricides is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, NanoViricides' Accounts Payable is projected to decrease significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 14 M, whereas Total Current Liabilities is forecasted to decline to about 583.7 K. Key indicators impacting NanoViricides' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.00450.0047
Notably Down
Slightly volatile
Current Ratio11.8914.23
Fairly Down
Pretty Stable
The financial analysis of NanoViricides is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for NanoViricides includes many different criteria found on its balance sheet. For example, investors should never minimize NanoViricides' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor NanoViricides' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in NanoViricides.

Net Income

(8.12 Million)

With this module, you can analyze NanoViricides financials for your investing period. You should be able to track the changes in NanoViricides individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past NanoViricides Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of NanoViricides' financial statements are interrelated, with each one affecting the others. For example, an increase in NanoViricides' assets may result in an increase in income on the income statement.
Evaluating NanoViricides' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of NanoViricides' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the NanoViricides' relative financial performance

Chance Of Distress

Less than 8

 
100  
 
Zero
Low
NanoViricides has less than 8 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for NanoViricides stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, NanoViricides' odds of distress score SHOULD NOT be confused with the real chance of NanoViricides filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as NanoViricides is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include NanoViricides' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in NanoViricides' official financial statements usually reflect NanoViricides' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of NanoViricides. For example, before you start analyzing numbers published by NanoViricides accountants, it's critical to develop an understanding of what NanoViricides' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of NanoViricides' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NanoViricides' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in NanoViricides' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NanoViricides. Please utilize our Beneish M Score to check the likelihood of NanoViricides' management manipulating its earnings.

NanoViricides Company Summary

NanoViricides competes with Agilent Technologies, Moleculin Biotech, Seres Therapeutics, Equillium, and Kineta. NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company was founded in 2005 and is based in Shelton, Connecticut. Nanoviricides operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 17 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNYSE MKT Exchange
CIK Number0001379006
ISINUS6300873022
CUSIP630087203 630087302 630087104
RegionNorth America
LocationConnecticut; U.S.A
Business Address1 Controls Drive,
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.nanoviricides.com
Phone203 937 6137
CurrencyUSD - US Dollar
You should never invest in NanoViricides without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of NanoViricides Stock, because this is throwing your money away. Analyzing the key information contained in NanoViricides' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

NanoViricides Key Financial Ratios

Generally speaking, NanoViricides' financial ratios allow both analysts and investors to convert raw data from NanoViricides' financial statements into concise, actionable information that can be used to evaluate the performance of NanoViricides over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that NanoViricides reports annually and quarterly.

NanoViricides Key Balance Sheet Accounts

201920202021202220232024 (projected)
Other Current Liab630.8K55.8K260.1K377.2K433.8K706.2K
Retained Earnings(105.6M)(114.4M)(122.5M)(131.1M)(118.0M)(112.1M)
Accounts Payable380.7K200.0K58.0K157.1K141.4K274.0K
Total Liab2.2M351.1K412.8K2.0M2.3M4.3M
Common Stock9.1K11.5K11.6K116.0104.499.18
Total Assets23.9M30.3M23.5M16.9M19.4M20.7M
Net Debt(12.6M)(20.4M)(14.0M)(8.1M)(7.3M)(7.7M)
Cash13.7M20.5M14.1M8.1M9.4M13.7M
Other Current Assets277.1B307.1B350.0K295.5K339.8K322.8K
Total Current Assets14.0M20.8M14.4M8.4M9.7M14.1M
Intangible Assets358.4K350.1K341.8K333.6K383.6K357.5K
Net Tangible Assets21.4M29.6M22.7M14.5M16.7M22.0M
Net Invested Capital22.9M30.0M23.2M14.9M17.1M22.5M

NanoViricides Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what NanoViricides' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense93.7K85.4K5.1K938.01.1K1.0K
Operating Income(8.0M)(8.7M)(8.1M)(8.9M)(8.0M)(8.5M)
Ebit(8.0M)(8.7M)(8.1M)(8.6M)(7.7M)(8.1M)
Research Development4.7M6.1M5.8M6.4M7.4M4.2M
Ebitda(7.4M)(8.0M)(7.4M)(7.8M)(7.1M)(7.4M)
Net Income(13.4M)(8.9M)(8.1M)(8.6M)(7.7M)(8.1M)
Income Tax Expense(49.0K)85.4K(6.7K)355.8K320.3K304.2K
Income Before Tax(13.4M)(8.8M)(8.1M)(8.6M)(9.9M)(10.4M)
Gross Profit(699.7K)(704.5K)(723.3K)(747.5K)(672.8K)(639.1K)
Cost Of Revenue699.7K704.5K723.3K747.5K859.7K902.6K
Net Interest Income(76.6K)(76.1K)6.7K354.9K408.1K428.5K
Interest Income17.1K9.3K11.9K355.8K409.2K429.7K

NanoViricides Key Cash Accounts

Cash flow analysis captures how much money flows into and out of NanoViricides. It measures of how well NanoViricides is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money NanoViricides brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money NanoViricides had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what NanoViricides has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Capital Expenditures8.6K238.8K324.3K151.7K174.5K165.7K
Net Income(13.4M)(8.8M)(8.1M)(8.6M)(7.7M)(8.1M)
Change In Cash11.2M6.8M(6.5M)(5.9M)(5.3M)(5.1M)
Free Cash Flow(6.7M)(8.5M)(6.2M)(5.8M)(5.2M)(5.5M)
Depreciation699.7K704.5K723.3K747.5K859.7K443.2K
Other Non Cash Items164.0K30.2K939.3K257.1K231.4K219.8K
End Period Cash Flow13.7M20.5M14.1M8.1M9.4M13.7M
Change To Netincome335.9K413.7K1.3M372.2K428.0K528.6K
Investments(8.6K)(238.8K)(324.3K)(151.7K)(174.5K)(183.2K)
Net Borrowings1.1M(1.3M)(234.7K)(94.8K)(85.3K)(81.0K)

NanoViricides Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining NanoViricides's current stock value. Our valuation model uses many indicators to compare NanoViricides value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NanoViricides competition to find correlations between indicators driving NanoViricides's intrinsic value. More Info.
NanoViricides is considered to be number one stock in z score category among related companies. It is considered to be number one stock in current ratio category among related companies fabricating about  0.48  of Current Ratio per Z Score. The ratio of Z Score to Current Ratio for NanoViricides is roughly  2.08 . At present, NanoViricides' Current Ratio is projected to increase based on the last few years of reporting.. Comparative valuation analysis is a catch-all model that can be used if you cannot value NanoViricides by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for NanoViricides' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NanoViricides' earnings, one of the primary drivers of an investment's value.

NanoViricides Systematic Risk

NanoViricides' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NanoViricides volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on NanoViricides correlated with the market. If Beta is less than 0 NanoViricides generally moves in the opposite direction as compared to the market. If NanoViricides Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NanoViricides is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NanoViricides is generally in the same direction as the market. If Beta > 1 NanoViricides moves generally in the same direction as, but more than the movement of the benchmark.

About NanoViricides Financials

What exactly are NanoViricides Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include NanoViricides' income statement, its balance sheet, and the statement of cash flows. Potential NanoViricides investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although NanoViricides investors may use each financial statement separately, they are all related. The changes in NanoViricides's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NanoViricides's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze NanoViricides Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as NanoViricides is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of NanoViricides has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if NanoViricides' financials are consistent with your investment objective using the following steps:
  • Review NanoViricides' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand NanoViricides' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare NanoViricides' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if NanoViricides' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in NanoViricides Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NanoViricides' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NanoViricides growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.3)

At present, NanoViricides' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

NanoViricides March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of NanoViricides help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NanoViricides. We use our internally-developed statistical techniques to arrive at the intrinsic value of NanoViricides based on widely used predictive technical indicators. In general, we focus on analyzing NanoViricides Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NanoViricides's daily price indicators and compare them against related drivers.
When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for NanoViricides Stock analysis

When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Global Correlations
Find global opportunities by holding instruments from different markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is NanoViricides' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.80)
Return On Assets
(0.36)
Return On Equity
(0.58)
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.